

1 **Changes in monocyte subsets can predict the risk of AAA and are surrogate markers**  
2 **for AAA morphology in patients with late-stage disease**

3 **Short title:** AAA, monocyte subsets, risk prediction, surrogate marker

4 Bianca Hamann<sup>1</sup>, Anna Klimova<sup>2</sup>, Marvin Kapalla<sup>1</sup>, David M. Poitz<sup>3</sup>, Frieda Frank<sup>1</sup>,  
5 Henning Morawietz<sup>4</sup>, Christian Reeps<sup>1\*</sup> and Anja Hofmann<sup>1\*</sup>

6 \*contributed equally

7 <sup>1</sup>Division of Vascular and Endovascular Surgery, Department of Visceral, Thoracic and  
8 Vascular Surgery, University Hospital and Medical Faculty Carl Gustav Carus, TUD Dresden  
9 University of Technology, Germany;

10 <sup>2</sup>Institute for Medical Informatics and Biometry, Faculty of Medicine, TUD Dresden  
11 University of Technology, Germany;

12 <sup>3</sup>Institute for Clinical Chemistry and Laboratory Medicine; University Hospital and Medical  
13 Faculty Carl Gustav Carus, TUD Dresden University of Technology, Germany;

14 <sup>4</sup>Division of Vascular Endothelium and Microcirculation, Department of Medicine III,  
15 University Hospital and Medical Faculty Carl Gustav Carus, TUD Dresden University of  
16 Technology, Germany;

17 **#Corresponding author:**

18 Anja Hofmann, PhD

19 Division of Vascular and Endovascular Surgery

20 Department of Visceral-, Thoracic and Vascular Surgery

21 Faculty of Medicine and University Hospital Carl Gustav Carus

22 TUD Dresden University of Technology

23 Fetscherstraße 74

24 D-01307 Dresden, Germany

25 Email: [anja.hofmann2@uniklinikum-dresden.de](mailto:anja.hofmann2@uniklinikum-dresden.de)


26

27 **Word count: 3.343 (Excluding references, figure legends and table legends)**

28 **Word count abstract: 217**

29 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

### 30 Graphical Abstract



**Findings**

	Classical monocytes CD14 <sup>++</sup> /CD16 <sup>-</sup>	Intermediate monocytes CD14 <sup>++</sup> /CD16 <sup>+</sup>	Non-classical monocytes CD14 <sup>+</sup> /CD16 <sup>++</sup>
Count in peripheral blood	↓	↑	↑
AAA risk	↑	↑	↑
AAA diameter	—	—	inverse
AAA volume	—	—	inverse
Intraluminal Thrombus	—	positive	—

31

32

33

34

35 **Abstract**

36 **Background** Monocytes play a pivotal role in pathology of abdominal aortic aneurysm (AAA)  
37 and can display an immunophenotypic heterogeneity with functionally distinct subpopulations.  
38 Alterations in monocyte subsets have been described in CVD, and some are associated with  
39 cardiovascular risk, but their profile in AAA is poorly understood. **Aim** We aimed to  
40 comprehensively define associations of circulating monocyte phenotypes with AAA risk and  
41 AAA morphology. **Methods** Monocyte subsets (CD14<sup>++</sup>CD16<sup>-</sup>; CD14<sup>++</sup>/CD16<sup>+</sup>;  
42 CD14<sup>+</sup>/CD16<sup>++</sup>) were analyzed in a prospective, observational study in patients with AAA  
43 (n=34) and varicose veins (n=34) by using flow cytometry. **Results** Classical monocytes were  
44 1.6-fold lower ( $P=0.001$ ) in AAA, while intermediate and non-classical monocytes were 1.8  
45 ( $P=0.019$ ) and 1.9-fold ( $P=0.025$ ) higher in AAA, respectively. The differences remained  
46 significant after adjusting for age, sex and peripheral artery disease. A lower proportion of  
47 classical monocytes (HR: 0.73,  $P=0.002$ ) and increases in intermediate (HR: 1.41,  $P=0.006$ )  
48 and non-classical monocytes (HR: 1.54,  $P=0.030$ ) were associated with a higher risk of AAA.  
49 Non-classical monocytes showed an inverse correlation with AAA diameter (Pearson  
50 correlation =-0.64,  $P=0.001$ ) and AAA volume (Pearson correlation =-0.50,  $P=0.003$ ).  
51 **Conclusion** The present study revealed age- and sex-independent shifts in monocytes, all of  
52 which were associated with risk of AAA disease. Non-classical monocytes were inversely  
53 correlated with AAA diameter and volume and thus may be surrogate markers for AAA  
54 morphology.

55 **Non-standard abbreviations and acronyms**

56 **AAA**, abdominal aortic aneurysm; **ACE**, angiotensin-converting enzyme; **ARBs**, angiotensin  
57 receptor blocker; **ASA**, acetylsalicylic acid; **BMI**, body mass index; **CAD**, coronary artery  
58 disease; **CAS**, carotid artery stenosis; **CCB**, calcium channel blocker; **CVD**, cardiovascular  
59 disease; **Hb**, hemoglobin; **HDL**, high-density lipoprotein cholesterol; **HF**, heart failure; **LDL**,  
60 low-density lipoprotein cholesterol; **PAD**, peripheral artery disease; **T2D**, Type 2 diabetes  
61 mellitus; **TC**, total cholesterol

62 **What's new?**

- 63 • Classical monocytes are lower in patients with late-stage AAA.
- 64 • Non-classical monocytes showed the strongest increase in AAA disease.
- 65 • A reduction in classical monocytes is associated with increased risk of AAA.
- 66 • An increase in non-classical and intermediate monocytes is associated with an increased  
67 risk of AAA.
- 68 • Lowering in non-classical monocytes may be a surrogate marker for AAA morphology,  
69 particularly AAA volume.
- 70 • Intermediate monocytes showed a positive correlation with the thickness of the  
71 intraluminal thrombus.

72

73 **What are the clinical implications?**

- 74 • The increase in non-classical monocytes could be a novel surrogate marker for AAA  
75 volume, which could be useful when AAA diameter is insufficient or to monitor a  
76 saccular AAA, as there is a weaker correlation between diameter and risk of rupture in  
77 this type of AAA.
- 78 • The decrease in classical monocytes could be a useful surrogate marker for AAA  
79 volume and provide additional information on AAA diameter.
- 80 • Monocyte shifts and their association with AAA disease may be relevant for the  
81 diagnosis of AAA and should be verified in larger cohorts.
- 82 • The mechanisms behind the decrease in classical monocytes and the increase in  
83 intermediate and non-classical subsets should be investigated in further *in vitro* studies  
84 as they offer therapeutic potential.

## 85 **Introduction**

86 Abdominal aortic aneurysm (AAA) is a life-threatening condition with high mortality rates.  
87 Main pathological features are inflammation with increased local cytokine production,  
88 extracellular matrix degradation, oxidative stress and the loss of smooth muscle cells.<sup>1</sup> The  
89 only effective treatment is surgical elimination of the AAA. Pharmacological treatments are  
90 still lacking, emphasizing the need to define the pathomechanisms that contribute to the  
91 initiation and progression of the disease. Inflammatory cells in AAA comprise monocytes,  
92 macrophages, neutrophils, mast cells, natural killer (NK) cells, T and B cells and dendritic  
93 cells.<sup>2</sup> Monocytes are recruited at sites of inflammation where they differentiate into  
94 macrophages.<sup>3</sup> Monocytes exist in subsets, which differ in morphology, function and cell  
95 surface marker (e.g. chemokine receptors) expression. Three distinct subsets were  
96 distinguished in humans based on the expression of the the LPS-receptor CD14 and the Fcγ  
97 receptor CD16: classical (CD14<sup>++</sup>CD16<sup>-</sup>), non-classical (CD14<sup>+</sup>CD16<sup>++</sup>) and intermediate  
98 (CD14<sup>++</sup>CD16<sup>+</sup>) monocytes.<sup>4</sup> Classical monocytes (CD14<sup>++</sup>CD16<sup>-</sup>) secrete large amounts  
99 of pro-inflammatory cytokines and promote angiogenesis, wound healing and coagulation,  
100 demonstrating their importance in tissue repair.<sup>3</sup> In contrast, CD16-expressing cells may  
101 secrete pro-inflammatory cytokines, have a high antigen-presenting capacity and the ability to  
102 migrate into subendothelial spaces and atherosclerotic lesions.<sup>4</sup> These cells include  
103 intermediate monocytes (CD14<sup>++</sup>CD16<sup>+</sup>), that secrete pro-inflammatory cytokines and  
104 accumulate in chronic inflammatory diseases.<sup>3,5,6</sup> Intermediate subsets are predictive for  
105 cardiovascular disease<sup>4</sup> and are associated, for example, with susceptibility to plaque  
106 vulnerability<sup>3</sup>. CD16<sup>+</sup> subsets are elevated in patients with AAA<sup>7</sup> and a recently published  
107 study showed that only intermediate monocytes (CD14<sup>++</sup>CD16<sup>+</sup>) were elevated in AAA  
108 compared to healthy individuals and patients with PAD<sup>8</sup>. Interestingly, CD14<sup>++</sup>CD16<sup>+</sup> and D-

109 dimer proved to be suitable diagnostic markers for AAA while elevated concentrations of these  
110 subsets were able to predict rapid growing AAA.<sup>8</sup>

111 Non-classical monocytes have low expression of CD14 (CD14+) and secrete pro- and anti-  
112 inflammatory cytokines. These monocytes have phagocytic properties to remove cell debris  
113 and are important for patrolling the vascular endothelium and controlling vascular integrity.  
114 Most likely, they are involved in the resolution of inflammation.<sup>3</sup> However, it should be noted  
115 that a CD14-low subset may promote neovascularization and destabilization of lesions, while  
116 their accumulation in ischemic tissue may have beneficial effects.<sup>4</sup>

117 Although an increase in intermediate subsets has been demonstrated in AAA, it is still under  
118 debate whether the three subgroups correlate with AAA diameter, AAA volume, and thickness  
119 of the intraluminal thrombus as the main morphologic features of AAA and could be useful  
120 surrogate markers. In addition, there is no information whether any of these monocyte subsets  
121 can predict end-stage AAA, when most patients with AAA are diagnosed. Here, we aimed to  
122 comprehensively define associations of circulating monocyte phenotypes with AAA risk and  
123 AAA morphology.

## 124 **Materials and Methods**

### 125 **Study Design**

126 Monocyte subpopulations were determined in an observational study in electively treated AAA  
127 patients and patients with varicose veins who served as controls. Due to the observational  
128 nature of the study, no sample size or power calculation was performed, according to the  
129 STROBE guidelines.<sup>9</sup> Patients were treated in the Department of Visceral, Thoracic and  
130 Vascular Surgery between December 2020 and June 2024. The diagnostic criteria for varicose  
131 patients included venous reflux assessed by duplex ultrasound and signs of chronic venous  
132 insufficiency according to the CEAP classification.<sup>10</sup> Inclusion criteria were age over 50 years  
133 and no known history of arterial disease, T2D and infectious diseases. Patients with  
134 thrombophlebitis were excluded. Inclusion criteria for AAA patients were a diameter of the  
135 infrarenal aorta of more than 40 mm, a rapidly growing AAA with more than 10 mm  
136 progression per year or a symptomatic AAA. The study was approved by the ethics committee  
137 of the Technische Universität Dresden (EK 151042017). Informed consent was obtained from  
138 all study participants.

### 139 **Outcome Variables**

140 Counts of each monocyte subset were defined as the primary outcome variable in the  
141 multivariate logistic regression, while AAA disease was defined as the outcome variable in the  
142 hazard ratio analysis.

143

### 144 **Clinical Parameters**

145 Serum low-density (LDL) and high-density (HDL) lipoprotein, total cholesterol (TC),  
146 triglycerides, non-fasting glucose, hemoglobin (Hb), leukocyte, and C-reactive protein (CRP)  
147 concentrations were analyzed in the Institute for Clinical Chemistry and Laboratory Medicine  
148 at the TU Dresden using standard laboratory methods. Due to the lack of data on blood



149 chemistry or medical therapies, the number of analyzed patients varies in each group.  
150 Cardiovascular risk factors, comorbidities, and prescribed medical therapies were evaluated  
151 retrospectively. Hypertension, type 2 diabetes (T2D), heart failure (HF), peripheral artery  
152 disease (PAD), and carotid artery stenosis (CAS) were defined by a past documented history  
153 of diagnosis or any treatment for these diseases. CAD was defined by a history of myocardial  
154 infarction, angina, or treatment for CAD. Smoking was defined as any history of smoking and  
155 sex was self-reported.

156

### 157 **Analysis of AAA Diameter and AAA Morphology**

158 The aortic diameter, maximal intraluminal thrombus depth and aortic volumes were determined  
159 as described previously.<sup>11</sup> In brief, aortic diameter was assessed by computed tomography  
160 angiography by measuring the distance between the outer adventitia (outer-to-outer-edge) by a  
161 single trained observer. Thickness of the ILT was determined in the arterial phase on CT scans  
162 following multiplanar reconstruction. The aorta was scanned in an axial position in 1 mm  
163 sections. The thickness of the ILT was assessed at the largest distance from the inner surface  
164 of the lumen to the outer aortic wall. The AAA volume was measured by two trained people  
165 using the automatic segmentation model of the IMPAX EE R20 software (Agfa HealthCare,  
166 Mortsel, Belgium). The aorta was scanned with contrast media in the arterial phase in 1 mm  
167 sections. The outer wall of the aneurysm and the true lumen were selected manually every  
168 6 mm in the transverse plane. The starting point of the measurement was defined as the cranial  
169 end of the aneurysm with a diameter greater than 30 mm. The measurement ended caudal to  
170 the dilation or at the aortic bifurcation. Non-recognized areas were cropped manually. The  
171 volume of AAA is given in cm<sup>3</sup>. The ILT was included in the total AAA volume measurement  
172 but was not specifically tagged for segmentation.

173

## 174 **Blood Samples and Flow Cytometry**

175 Non-fasting venous blood was collected pre-operatively between 2020 and 2024 in 9 mL  
176 S-Monovette EDTA (Sarstedt, Nürnberg, Germany). Monocyte subpopulations were  
177 analyzed using flow cytometry. Cells were stained for 10 min using the following antibody  
178 cocktail: CD45-FITC (HI-30, Thermo Fisher Scientific, Darmstadt, Germany), CD16-  
179 PerCP710 (CB16, Thermo Fisher Scientific Darmstadt, Germany) and CD14-PE (M $\phi$ P9, BD  
180 Biosciences, Heidelberg, Germany). Isotype controls were prepared to ensure selectivity of the  
181 antibodies. Afterwards, erythrocytes were lysed by the addition of FACS lysing solution (BD  
182 Biosciences, Heidelberg, Germany) for 10 min. Data acquisition was performed on LSR  
183 Fortessa (BD Biosciences, Heidelberg, Germany) and LSR II (BD Biosciences, Heidelberg,  
184 Germany). Data analysis was performed using FlowJo<sup>TM</sup> Software (Version 10, BD  
185 Biosciences, Heidelberg, Germany). First, debris was excluded by applying SSC and FSC, and  
186 events with low FSC and SSC signals were omitted. Before cell aggregates were excluded from  
187 the analysis, expression of CD45 against the SSC signal was used to select the monocyte  
188 population for further analysis. Finally, classical (CD14<sup>++</sup>CD16<sup>-</sup>), non-classical  
189 (CD14<sup>+</sup>CD16<sup>++</sup>) and intermediate (CD14<sup>++</sup>CD16<sup>+</sup>) monocytes were determined according  
190 to their expression of CD14 and CD16 (**Supplementary Figure 1**).

191

## 192 **Statistics**

193 Graph Pad Prism 10.0 (GraphPad Software, Inc., La Jolla, CA, USA) and R Core Team (2021)  
194 R: A Language and Environment for Statistical Computing software (R Foundation for  
195 Statistical Computing, Vienna/Austria) were used for statistical analysis. A *P*-value  $\leq 0.05$  was  
196 considered significant. Outliers were tested with the Grubbs outlier test and normality  
197 distribution with the D'Agostino and Pearson test. According to the result of the normal  
198 distribution test, Mann–Whitney U or unpaired t-test were used to compare AAA and varicose

199 vein patients. Data are shown as box plots with individual values or as scatter dot plots, as  
200 indicated in the figure legends. Correlational analysis was done using Pearson correlation ( $r_p$ ).  
201 Weighted linear regression was performed for variable selection, to assess the influence of age,  
202 sex, smoking, hypertension, T2D, CAD, PAD, CRP, HDL-, LDL cholesterol, triglyceride,  
203 hemoglobin, leukocyte count, AAA diameter, thickness of the ILT and prescription of insulin,  
204 diuretics, statins, ACE, CCB, ARBs,  $\beta$ -blocker, ASA and therapeutic anticoagulation. As some  
205 comorbidities strongly influence each other, only age and sex were included in the final  
206 analysis. In addition, PAD was included in the multivariate analysis as patients already served  
207 as a control group in numerous studies.<sup>8</sup> Data were analyzed by multivariate logistic regression  
208 using each of the monocyte subgroups as a independent variable for the presence of AAA  
209 disease. Subgroup concentrations were log transformed, and the effect of risk factors was  
210 compared with patients in whom the risk factor was not present.

## 211 **Results**

### 212 **Patient Characteristics**

213 The comparison of AAA and venous vein patient's revealed that the AAA group was  
214 significantly older and comprised more male patients than varicose vein controls. As expected,  
215 both groups differed in their prevalence of cardiovascular risk factors and prescribed  
216 pharmacotherapy. A detailed list of risk factors and pharmacotherapy is given in **Table 1**.

217

### 218 **Phenotypic Heterogeneity of Monocyte Subsets in AAA Patients**

219 In the present study, significant shifts in monocyte subsets were observed in AAA patients  
220 compared to controls with varicose veins. In patients with an AAA, there were 1.6-fold lower  
221 ( $P=0.001$ ) counts for classical monocytes and 1.9-fold ( $P=0.025$ ) and 1.8-fold ( $P=0.019$ )  
222 higher counts for non-classical monocytes and intermediates, respectively (**Figure 1**). To  
223 determine which of the patients' risk factors and comorbidities influenced the subgroups the  
224 most, we performed a linear weighted regression. We found that classical monocytes are  
225 relatively robust, since they are barely affected by any of the investigated comorbidities and  
226 risk factors (**Supplementary Table 1**). In non-classical monocytes, PAD was associated with  
227 an increase, and T2D as well as hypertension were associated with a decrease in this subset  
228 (**Supplementary Table 2**). Intermediate monocytes were strongly influenced by the presence  
229 of T2D, while sex and hypertension were associated with a decrease in this subset  
230 (**Supplementary Table 3**). All the investigated comorbidities and risk factors were seen to  
231 highly confound each other. We therefore performed a logistic regression analysis and chose  
232 age, sex and PAD for adjustment to analyze whether these factors influence the observed  
233 differences between varicose veins and AAA. After adjusting for age, sex and PAD the  
234 observed decrease in classical monocytes ( $P=0.001$ ) and increase in non-classical monocytes  
235 ( $P=0.040$ ) in AAA patients remained significant (**Table 2**).

## 236 **Monocyte Subsets, AAA Risk and Associations with AAA Morphology**

237 Hazard ratios were calculated to test whether differences in monocyte subgroups lead to an  
238 increased risk of AAA disease. A reduced number of classical monocytes was associated with  
239 an increased risk of AAA ( $P=0.002$ ). Furthermore, increased levels of non-classical ( $P=0.030$ )  
240 and intermediate monocytes ( $P=0.006$ ) led to a higher risk for AAA disease (**Table 3**).

241

## 242 **Monocytes and Correlations with AAA Morphology**

243 A correlational analysis was performed to test whether the different monocyte subgroups  
244 correlate with the morphology of the AAA and can therefore serve as surrogate markers.  
245 Classical monocytes showed a trend to increase with AAA diameter (**Figure 2A**), while no  
246 correlations with AAA volume or ILT thickness were found (**Table 4**). Conversely, non-  
247 classical monocytes decreased with increasing AAA diameter ( $r_p=-0.64$ ,  $P<0.001$ ) and  
248 increasing AAA volume ( $r_p=-0.50$ ,  $P=0.003$ ) (**Figure 2B,C**). Intermediate monocytes showed  
249 a trend towards a positive association with maximum depth of the ILT ( $r_p=0.32$ ,  $P=0.067$ )  
250 (**Figure 2D**). **Table 4** provides an extended overview of the tested correlations.

## 251 Discussion

252 Monocytes are important inflammatory mediators in cardiovascular disease and also in AAA  
253 as a particular CVD. Depending on the expression of their surface markers, monocytes are  
254 classified into different subgroups that have different functions. Knowledge about their  
255 expression patterns may contribute to the understanding of specific disease mechanisms as  
256 these cells migrate into inflamed tissue and differentiate into macrophages. Moreover, this  
257 would allow the identification of patients at high risk and provide useful surrogate markers for  
258 AAA morphology. Although an increase in intermediate subsets has been demonstrated in  
259 AAA<sup>8</sup>, nothing is known whether these subsets correlate with AAA diameter, AAA volume  
260 and intraluminal thrombus as main morphologic features of AAA. Determination of surrogate  
261 markers that correlate with the maximum AAA diameter is of great interest, as the AAA  
262 diameter is the most important marker for decisions on surgical therapy.<sup>12</sup> Furthermore, there  
263 is no information on whether any of these subgroups can predict the risk of having AAA.  
264 The present study showed a lower count of classical monocytes (CD14<sup>++</sup>CD16<sup>-</sup>) and higher  
265 counts of intermediate (CD14<sup>++</sup>CD16<sup>+</sup>) and non-classical monocytes (CD14<sup>+</sup>CD16<sup>++</sup>) in  
266 patients with AAA. Our data are, at least in part, supported by previously published studies.<sup>7,8</sup>  
267 The decreased proportion of classical monocytes could be explained by findings in mice after  
268 induction of acute myocardial infarction. In the first phase, CD14<sup>+</sup>CD16<sup>-</sup> monocytes  
269 accumulate early at the site of injury to clear necrotic debris and promote healing of the  
270 damaged tissue. CD14<sup>+</sup>CD16<sup>++</sup> dominate in the second phase and promote healing through  
271 the accumulation of myofibroblasts, angiogenesis and collagen deposition.<sup>13</sup> The data herein  
272 eventually underline an imbalance between both subsets in patients with AAA towards  
273 intermediate subsets that promote fibrotic remodeling in the AAA wall. While non-classical  
274 monocytes remain in the bloodstream, classical monocytes could transmigrate through the

275 endothelium into the vessel wall.<sup>14</sup> This could be a possible explanation for the depletion of the  
276 classic monocytes, which could be due to an increased migration into the AAA.  
277 Non-classical monocytes are the most inflammatory subset but also show patrolling function.<sup>15</sup>  
278 Studies in patients with CAD<sup>16</sup> and subclinical atherosclerosis demonstrated increased non-  
279 classical subsets<sup>17</sup> and therefore coincidence the data of the present study. Herein, a higher  
280 count of non-classical was found in AAA, which is different to data previously published by  
281 Klopff et al.<sup>8</sup> Most often, patients with PAD served as controls in biomarker studies in AAA.<sup>18</sup>  
282 PAD is one of the most common initial manifestations of T2D<sup>19</sup> and T2D itself is inversely  
283 associated with AAA disease.<sup>20</sup> It might be of speculation that a confounding of protective and  
284 adverse effects could occur.

285 To further understand the link between AAA risk and blood monocytes, we analyzed whether  
286 a specific subtype of monocyte was associated with increased risk of having AAA disease. We  
287 were able to show that a lower proportion of classical monocytes was associated with a higher  
288 risk of AAA, while an increase in non-classical and intermediate monocytes was associated  
289 with an increased risk of AAA. It could be that the increase in intermediate and non-classical  
290 subsets occurs at the expense of classical monocytes. Similar results were demonstrated in  
291 patients with T2D.<sup>21</sup> Intermediate monocytes have been demonstrated to be an independent  
292 predictor of cardiovascular events in patients with atherosclerotic diseases.<sup>22</sup> Similar results  
293 were obtained for non-classical monocytes.<sup>22</sup> The increased risk might be explained by the  
294 proinflammatory role of intermediate and non-classical monocytes.<sup>22</sup> Interestingly, the  
295 percentage of classical monocytes might be a protective factor for major adverse outcomes in  
296 coronary artery disease.<sup>23</sup> Classical monocytes are known to be phagocytic but have no  
297 inflammatory potential.<sup>15</sup> Given their protective role, the decrease in AAA and their association  
298 with AAA risk might be a hint to a loss of their function.

299 The higher percentage of non-classical, CD14<sup>+</sup>CD16<sup>++</sup> monocytes was inversely associated  
300 with the AAA diameter and AAA volume. Analyzing the AAA volume has the advantage of  
301 including the morphology of the aneurysm.<sup>24</sup> AAA volume can be useful when the diameter  
302 fails or for monitoring saccular AAA, since there is a weaker correlation between increased  
303 diameter and rupture risk in this type of AAA.<sup>25</sup> Finally, AAA volume might be a better  
304 predictor for AAA growth.<sup>26</sup> A negative correlation between non-classical, CD14<sup>+</sup>CD16<sup>++</sup>  
305 monocytes with the intima-media-thickness was shown in patients with carotid artery stenosis<sup>27</sup>  
306 and in peripheral artery disease where non-classical subsets decreased with the severity<sup>5</sup>.  
307 CD14<sup>+</sup>CD16<sup>++</sup> monocytes (or Ly-6C<sup>lo</sup> in mice) are involved in healing of the ischemic  
308 myocardium and they initiate the differentiation towards M2 macrophages, known to be  
309 involved in tissue repair. It might be of speculation, but the inverse relationship could be  
310 explained by temporal patterns and lack of their protective and healing functions<sup>27</sup>, although  
311 they are higher in patients with AAA. Another possibility that could explain the inverse  
312 relationship between AAA diameter and non-classical monocytes is that non-classical  
313 monocytes migrate into the AAA, i.e. as the diameter increases, more cells migrate in and their  
314 concentration in the blood decreases. In addition, the patients examined here are in the final  
315 stage of the disease and exhibit the typical degeneration of the AAA wall.<sup>18,28</sup>

316 The majority of AAA are covered by an intraluminal thrombus (ILT). The ILT contains fibrin,  
317 inflammatory cells, platelets and red blood cells and affects growth and rupture of the AAA.<sup>29,30</sup>  
318 Herein, intermediate (CD14<sup>++</sup>CD16<sup>+</sup>) subsets tended to correlate with the thickness of the  
319 ILT in AAA-patients. Intermediate monocytes are capable of antigen presentation, secreting  
320 pro-inflammatory cytokines and to regulate immune responses.<sup>31</sup> It has been demonstrated that  
321 intermediate monocytes are present in the ILT but in lower amounts than in peripheral blood  
322 of AAA patients.<sup>32</sup> The positive association could reflect the inflammatory nature of the ILT  
323 or also cells that are released by the ILT.



324 Overall, the present study showed age- and sex-independent shifts in classical, non-classical  
325 and intermediate subsets in AAA, suggesting disease-specific mechanisms. An decrease in  
326 classical monocytes and the increases in intermediate and non-classical monocytes were  
327 associated with risk for having AAA. The number of non-classical monocytes correlated  
328 inversely with AAA diameter and AAA volume and could therefore be a useful surrogate  
329 marker for AAA morphology, beyond the AAA diameter. Especially the lowering in  
330 phagocytic classical monocytes and the increase in non-classical monocytes should be  
331 considered in future studies.

332 **Limitations**


333 The present study is a descriptive, observational study on a very small cohort of patients.  
334 Varicose vein patients were used as a control group and their limitation is their different  
335 comorbidity and risk factor profile. The relatively small number of patients included and the  
336 large number of confounding factors may have influenced the results. Analyzing patients in  
337 whom the risk factors have been adjusted prior, e.g. in a case-control study, could minimize  
338 these effects. Furthermore, the results obtained here do not allow to establish a causal  
339 relationship between the different monocyte subsets and the development of AAA which is due  
340 to the study design. Finally, the main discrepancy when comparing data from flow cytometry  
341 with the present study is the pre-selection of cells, the declaration of subgroups based on the  
342 expression of CD14 and CD16 and the gating strategy in flow cytometry.

343

344 **Acknowledgement**


345 Flow cytometry measurement and analysis was done at the Flow Cytometry Core Facility at  
346 TU Dresden, University of Technology. We would like to thank Dr Anne Gompf, Head of the  
347 Flow Cytometry Core Facility, for her excellent technical experience.

348 **Figures**



349

350 **Figure 1: Monocyte Subsets in Patients with AAA and Varicose Vein Controls.** Non-  
351 fasting venous-blood was collected and the relative frequency of the individual monocyte  
352 subpopulations was determined by flow cytometry. **A**, classical (CD14++CD16-), **B**, non-  
353 classical (CD14+CD16++) and **C**, intermediate (CD14++CD16+) monocytes. All data are  
354 shown as boxplots with individual values. Outliers were identified using the Grubb's outlier  
355 test and one patient in each group was excluded from all further analysis. **A**, Unpaired t-test,  
356 **B-C**, Mann-Whitney U test.



357

358 **Figure 2: Correlation of Monocyte Subsets and AAA Morphology.** Monocyte subsets were  
359 analyzed using flow cytometry and are given as % of total monocytes. The data were  
360 logarithmically transformed and analyzed for correlations with the morphology of the AAA.  
361 Correlation of **A**, classical monocytes with AAA diameter, **B**, AAA diameter and non-classical  
362 monocytes, **C**, non-classical monocytes and AAA volume and **D**, ILT and intermediate  
363 monocytes. **Statistics:** Grubb's outlier test was used to identify outliers. One AAA patient was  
364 identified as an outlier and excluded from all further analysis. Correlational analysis was done  
365 using the Pearson correlation.  $r_p$ , Pearson rank correlation coefficient.

366 **Tables**

367 **Table 1: Clinical Characteristics in Patients with Abdominal Aortic Aneurysm (AAA)**

368 **and Venous Vein varicose.** Blood was taken in the non-fasted state. Reference values for the  
 369 corresponding blood parameters are given in the table. Reference values for LDL and total  
 370 cholesterol (TC) are based on the European Society of Cardiology (ESC) recommendations.  
 371 Reference values for fasting glucose were excluded due to the withdrawal in the non-fasted  
 372 state. **Statistics:** All data are presented as median with minimum and maximum values.  
 373 Comparison of continuous data was done using the Mann-Whitney U test or t-test. Discrete  
 374 data were analyzed by Chi-Square test. For t test (a) t-statistic is reported, Mann-Whitney (b)  
 375 U statistics and Chi-square (c)  $X^2$  is reported. **Abbreviations:** ACE, angiotensin-converting  
 376 enzyme; ARBs, angiotensin receptor blocker; BMI, body mass index; ASA, acetylsalicylic  
 377 acid; CAD, coronary artery disease; CCB, calcium channel blocker; HDL, high-density  
 378 lipoprotein; LDL, low-density lipoprotein; PAD, peripheral artery disease; T2D, type 2  
 379 diabetes mellitus; TIA, transient ischemic attack.

380

<b>Observational study</b>				
	Varicosis	eAAA	<i>P</i> -value	Statistics
<b>Baseline demographics</b>				
n included	33	33		
Age – years, mean ± SD	62.79 ± 8.15	70.39 ± 9.41	<0.001 <sup>a</sup>	t=3.51
Sex, male:female, % male	20:13, 61	30:3, 91	0.0041 <sup>c</sup>	$X^2=8.25$

<b>Hematology</b>				
Hemoglobin – mmol/L, mean ± SD, n	8.99 ± 0.73 32	9.01 ± 1.10 33	0.948 <sup>a</sup>	t=0.07
Reference values 8.60 – 12.10 mmol/L				
Leukocytes – GPt/L, mean ± SD, n	6.83 ± 1.48 32	7.64 ± 1.68 33	0.046 <sup>a</sup>	t=2.04
Reference values 3.8 – 9.8 GPt/L				
<b>Cardiovascular risk factors</b>				
LDL cholesterol – mmol/L, mean ± SD, n	4.18 ± 1.50 31	3.28 ± 1.36 33	0.014 <sup>a</sup>	t=2.53
Reference values <1.40 mmol/L for people with very-high risk				
HDL cholesterol – mmol/L, median with range, n	1.63 (1.00 – 2.62) 31	1.28 (0.75 – 1.98) 33	0.015 <sup>b</sup>	U=331.00
Reference values >0.90 mmol/L for men and >1.10 mmol/L for women				
Total cholesterol – mmol/L, mean ± SD, n	4.57 ± 1.37 31	3.52 ± 1.55 33	0.006 <sup>a</sup>	t=0.85
Reference values <4.00 mmol/L				

Triglycerides – mmol/L, median with range, n	1.18 (0.43 – 3.88) 31	1.20 (0.52 – 3.59) 32	0.582 <sup>b</sup>	U=455.50
Reference values 0.35 – 1.70 mmol/L				
Blood glucose – mmol/L, median with range, n	5.37 (4.30 – 6.81) 28	5.94 (4.69 – 11.33) 30	0.004 <sup>b</sup>	U=238.50
Reference value only for fasting glucose possible				
CRP – mg/L, median with range, n	1.30 (0.50 – 21.30) 31	2.65 (0.60 – 16.80) 31	0.049 <sup>b</sup>	U=353.50
Reference values <5.0 mg/L				
Smoking, yes:no – %	6:27, 18	23:10, 70	<0.001 <sup>c</sup>	X <sup>2</sup> =17.78
Hypertension, yes:no – %	11:22, 33	30:3, 91	<0.001 <sup>c</sup>	X <sup>2</sup> =23.24
CAD, yes:no – %	0:33, 0	10:23, 30	0.001 <sup>c</sup>	X <sup>2</sup> =11.79
HF, yes:no – %	1:32, 3	10:23, 30	0.003 <sup>c</sup>	X <sup>2</sup> =8.84
CAS, yes:no – %	0:33, 0	7:26, 21	0.005 <sup>c</sup>	X <sup>2</sup> =7.83
PAD, yes:no – %	0:33, 0	8:25, 24	0.003 <sup>c</sup>	X <sup>2</sup> =9.10
T2D, yes:no – %	0:33, 0	11:22, 33	<0.001 <sup>c</sup>	X <sup>2</sup> =13.20

BMI – kg/m <sup>2</sup> , median with range, n	27.20 (21.20 – 40.70) 33	27.25 (20.30 – 38.01) 33	0.677 <sup>b</sup>	U=511.50
<b>Pharmacological therapies</b>				
Statins, yes:no – %	3:29, 9	24:9, 73	<0.001 <sup>c</sup>	X <sup>2</sup> =26.85
ACE inhibitors, yes:no – %	3:29, 9	15:18, 45	0.001 <sup>c</sup>	X <sup>2</sup> =10.56
ARB, yes:no – %	4:28, 13	13:20, 39	0.014 <sup>c</sup>	X <sup>2</sup> =6.08
CCB, yes:no – %	2:30, 6	13:20, 39	0.002 <sup>c</sup>	X <sup>2</sup> =10.05
ASA, yes:no – %	2:30, 6	25:8, 76	<0.001 <sup>c</sup>	X <sup>2</sup> =32.32
b-blocker, yes:no – %	4:28, 13	17:16, 52	<0.001 <sup>c</sup>	X <sup>2</sup> =11.31
Anticoagulation, yes:no – %	6:26, 19	3:30, 9	0.260 <sup>c</sup>	X <sup>2</sup> =1.27
Antiplatelet, yes:no – %	1:31, 3	3:30, 9	0.317 <sup>c</sup>	X <sup>2</sup> =1.00
Diuretics, yes:no – %	4:28, 13	9:24, 27	0.137 <sup>c</sup>	X <sup>2</sup> =1.49
T2D treatment, yes:no – %	0:32, 0	11:22, 33	<0.001 <sup>c</sup>	X <sup>2</sup> =12.84
Insulin, yes:no – %	0:32, 0	2:31, 6	0.157 <sup>c</sup>	X <sup>2</sup> =2.00



382 **Table 2: Differences in Monocyte Subsets after Adjusting to Age, Sex and PAD.** Monocyte  
 383 subsets were analyzed using flow cytometry and monocytes are given in % of total monocytes.  
 384 Data were analyzed by multivariate logistic regression using each of the monocyte subgroups  
 385 as a diagnostic variable for the presence of AAA disease. The monocyte subgroups were  
 386 logarithmically transformed, and data were analyzed by multivariate logistic regression using  
 387 the corresponding subset as a predictor variable. The effects of each risk factor were compared  
 388 with patients in whom the risk factor was not present (ref=none). The odds ratio (OR) refers to  
 389 the relative increase in risk of AAA disease as the percentage of the subgroup increases on the  
 390 logarithmic scale. For sex, ORs refer to men and reference values refer to women. AAA  
 391 diameter and age show the increase per unit (year and mm, respectively). Unadjusted values  
 392 were obtained by pairwise comparison of each variable listed in the table with the outcome of  
 393 having an AAA. Adjusted values were analyzed by holding the effects of the other variables  
 394 constant and assuming an increase in the monocyte subset on the logarithmic scale.  
 395 **Abbreviations:** OR, odds ratio.

396

<b>Variable</b>	<b>Unadjusted OR [95% CI]</b>	<b>P-value</b>	<b>Adjusted OR [95% CI]</b>	<b>P-value</b>
<b>classical monocytes [log10]</b>				
Group (ref=varicosis)	0.973 [0.958, 0.987]	<0.001	0.968 [0.949, 0.987]	0.001
Age (years)	0.999 [0.998, 1.000]	0.076	1.000 [0.999, 1.001]	0.950
Sex (ref=female)	1.001 [0.982, 1.021]	0.895	1.014 [0.994, 1.035]	0.160

PAD (ref=none)	0.987 [0.963, 1.012]	0.308	1.004 [0.980, 1.029]	0.754
<b>non-classical monocytes [log10]</b>				
Group (ref=varicosis)	1.504 [1.019, 2.220]	0.040	1.760 [1.058, 2.928]	0.030
Age (years)	1.002 [0.981, 1.024]	0.830	0.988 [0.964, 1.012]	0.331
Sex (ref=female)	1.024 [0.635, 1.652]	0.921	0.784 [0.462, 1.330]	0.360
PAD (ref=none)	1.283 [0.697, 2.360]	0.417	1.026 [0.537, 1.960]	0.937
<b>intermediate Monocytes [log10]</b>				
Group (ref=varicosis)	1.674 [0.988, 2.836]	0.055	1.940 [0.987, 3.814]	0.054
Age (years)	1.024 [0.996, 1.053]	0.091	1.007 [0.975, 1.040]	0.680
Sex (ref=female)	0.709 [0.375, 1.343]	0.287	0.563 [0.279, 1.136]	0.107
PAD (ref=none)	1.203 [0.527, 2.745]	0.656	0.857 [0.363, 2.024]	0.721

397

398

399 **Table 3: Hazard Ratios of Monocyte Subsets and AAA risk.** Monocyte subsets were  
400 analyzed using flow cytometry and monocytes are given in % of total monocytes. Logistic  
401 regression was used to obtain hazard ratio of incident AAA per one unit increase in monocytes  
402 subsets on log scale.

	<b>Hazard Ratio</b> <b>[95% CI]</b>	<b>P-value</b>
<b>Classical monocytes</b>	0.726 [0.584, 0.874]	0.002
<b>Intermediate monocytes</b>	1.412 [1.123, 1.846]	0.006
<b>Non-classical monocytes</b>	1.537 [1.068, 2.354]	0.030

403

404 **Table 4: Summary of Correlations Between Monocyte Subsets and AAA Morphology.**

405 Monocyte subsets were analyzed using flow cytometry and monocyte subsets are given in %  
 406 of total monocytes. Data were log transformed. Correlational analysis was performed using  
 407 Pearson correlation. Outliers were identified using Grubb’s outlier test and excluded from  
 408 further analysis. **Abbreviations:** AAA, Abdominal aortic aneurysm, **ILT**, Intraluminal  
 409 thrombus, **r<sub>p</sub>**, Pearson’s rank correlation coefficient.

410

	classical monocytes		non-classical monocytes		intermediate monocytes	
	r <sub>p</sub>	P-value	r <sub>p</sub>	P-value	r <sub>p</sub>	P-value
<b>AAA diameter</b>	0.32	0.069	<b>-0.64</b>	<b>&lt;0.001</b>	-0.20	0.265
<b>ILT</b>	-0.21	0.23	0.19	0.298	<b>0.32</b>	<b>0.067</b>
<b>AAA volume</b>	0.27	0.13	<b>-0.50</b>	<b>0.003</b>	-0.13	0.481

411

412 References

- 413 1. Raffort J, Lareyre F, Clément M, Hassen-Khodja R, Chinetti G, Mallat Z. Monocytes and  
414 macrophages in abdominal aortic aneurysm. *Nat Rev Cardiol*. 2017;14:457–471. doi:  
415 10.1038/nrcardio.2017.52
- 416 2. Márquez-Sánchez AC, Koltsova EK. Immune and inflammatory mechanisms of  
417 abdominal aortic aneurysm. *Front Immunol*. 2022;13:989933. doi:  
418 10.3389/fimmu.2022.989933
- 419 3. Ruder AV, Wetzels SMW, Temmerman L, Biessen EAL, Goossens P. Monocyte  
420 heterogeneity in cardiovascular disease. *Cardiovasc Res*. 2023;119:2033–2045. doi:  
421 10.1093/cvr/cvad069
- 422 4. Hristov M, Leyendecker T, Schuhmann C, Hundelshausen P von, Heussen N, Kehmeier  
423 E, Krötz F, Sohn H-Y, Klauss V, Weber C. Circulating monocyte subsets and  
424 cardiovascular risk factors in coronary artery disease. *Thromb Haemost*. 2010;104:412–  
425 414. doi: 10.1160/TH10-01-0069
- 426 5. Wildgruber M, Aschenbrenner T, Wendorff H, Czubba M, Glinzer A, Haller B,  
427 Schiemann M, Zimmermann A, Berger H, Eckstein H-H, Meier R, Wohlgemuth WA,  
428 Libby P, Zerneck A. The "Intermediate" CD14<sup>++</sup>CD16<sup>+</sup> monocyte subset increases in  
429 severe peripheral artery disease in humans. *Sci Rep*. 2016;6:39483. doi:  
430 10.1038/srep39483
- 431 6. van der Laan AM, Hirsch A, Robbers LFHJ, Nijveldt R, Lommerse I, Delewi R, van der  
432 Vleuten PA, Biemond BJ, Zwaginga JJ, van der Giessen WJ, Zijlstra F, van Rossum AC,  
433 Voermans C, van der Schoot CE, Piek JJ. A proinflammatory monocyte response is  
434 associated with myocardial injury and impaired functional outcome in patients with ST-  
435 segment elevation myocardial infarction: monocytes and myocardial infarction. *Am Heart*  
436 *J*. 2012;163:57-65.e2. doi: 10.1016/j.ahj.2011.09.002
- 437 7. Ghigliotti G, Barisione C, Garibaldi S, Brunelli C, Palmieri D, Spinella G, Pane B,  
438 Spallarossa P, Altieri P, Fabbi P, Sambuceti G, Palombo D. CD16(+) monocyte subsets  
439 are increased in large abdominal aortic aneurysms and are differentially related with  
440 circulating and cell-associated biochemical and inflammatory biomarkers. *Dis Markers*.  
441 2013;34:131–142. doi: 10.1155/2013/836849
- 442 8. Klopff J, Zagraban B, Brandau A, Lechenauer P, Candussi CJ, Rossi P, Celem ND, Ziegler  
443 M, Fuchs L, Hayden H, Krenn CG, Eilenberg W, Neumayer C, Brostjan C. Circulating  
444 monocyte populations as biomarker for abdominal aortic aneurysms: a single-center  
445 retrospective cohort study. *Front Immunol*. 2024;15:1418625. doi:  
446 10.3389/fimmu.2024.1418625
- 447 9. Vandenbroucke JP, Elm E von, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole  
448 C, Schlesselman JJ, Egger M. Strengthening the Reporting of Observational Studies in  
449 Epidemiology (STROBE): explanation and elaboration. *PLoS Med*. 2007;4:e297. doi:  
450 10.1371/journal.pmed.0040297
- 451 10. Lurie F, Passman M, Meisner M, Dalsing M, Masuda E, Welch H, Bush RL, Blebea J,  
452 Carpentier PH, Maeseneer M de, Gasparis A, Labropoulos N, Marston WA, Rafetto J,  
453 Santiago F, Shortell C, Uhl JF, Urbanek T, van Rij A, Eklof B, Glocviczki P, Kistner R,  
454 Lawrence P, Moneta G, Padberg F, Perrin M, Wakefield T. The 2020 update of the CEAP  
455 classification system and reporting standards. *J Vasc Surg Venous Lymphat Disord*.  
456 2020;8:342–352. doi: 10.1016/j.jvsv.2019.12.075
- 457 11. Hamann B, Klimova A, Klotz F, Frank F, Jänichen C, Kapalla M, Sabarstinski P, Wolk S,  
458 Morawietz H, Poitz DM, Hofmann A, Reeps C. Regulation of CD163 Receptor in Patients  
459 with Abdominal Aortic Aneurysm and Associations with Antioxidant Enzymes HO-1 and  
460 NQO1. *Antioxidants (Basel)*. 2023;12. doi: 10.3390/antiox12040947

- 461 12. Wanhainen A, Mani K, Golledge J. Surrogate Markers of Abdominal Aortic Aneurysm  
462 Progression. *Arterioscler Thromb Vasc Biol.* 2016;36:236–244. doi:  
463 10.1161/ATVBAHA.115.306538
- 464 13. Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo J-L,  
465 Libby P, Weissleder R, Pittet MJ. The healing myocardium sequentially mobilizes two  
466 monocyte subsets with divergent and complementary functions. *J Exp Med.*  
467 2007;204:3037–3047. doi: 10.1084/jem.20070885
- 468 14. Feinstein MJ, Doyle MF, Stein JH, Sitlani CM, Fohner AE, Huber SA, Landay AL,  
469 Heckbert SR, Rice K, Kronmal RA, Hedrick C, Manichaikul A, McNamara C, Rich S,  
470 Tracy RP, Olson NC, Psaty BM, Delaney JAC. Nonclassical Monocytes  
471 (CD14dimCD16+) Are Associated With Carotid Intima-Media Thickness Progression for  
472 Men but Not Women: The Multi-Ethnic Study of Atherosclerosis-Brief Report.  
473 *Arterioscler Thromb Vasc Biol.* 2021;41:1810–1817. doi:  
474 10.1161/ATVBAHA.120.315886
- 475 15. Mukherjee R, Kanti Barman P, Kumar Thatoi P, Tripathy R, Kumar Das B, Ravindran B.  
476 Non-Classical monocytes display inflammatory features: Validation in Sepsis and  
477 Systemic Lupus Erythematosus. *Sci Rep.* 2015;5:13886. doi: 10.1038/srep13886
- 478 16. Urbanski K, Ludew D, Filip G, Filip M, Sagan A, Szczepaniak P, Grudzien G, Sadowski  
479 J, Jasiewicz-Honkisz B, Sliwa T, Kapelak B, McGinnigle E, Mikolajczyk T, Guzik TJ.  
480 CD14+CD16++ "nonclassical" monocytes are associated with endothelial dysfunction in  
481 patients with coronary artery disease. *Thromb Haemost.* 2017;117:971–980. doi:  
482 10.1160/TH16-08-0614
- 483 17. Poitou C, Dalmás E, Renovato M, Benhamo V, Hajduch F, Abdennour M, Kahn J-F,  
484 Veyrie N, Rizkalla S, Fridman W-H, Sautès-Fridman C, Clément K, Cremer I.  
485 CD14dimCD16+ and CD14+CD16+ monocytes in obesity and during weight loss:  
486 relationships with fat mass and subclinical atherosclerosis. *Arterioscler Thromb Vasc Biol.*  
487 2011;31:2322–2330. doi: 10.1161/ATVBAHA.111.230979
- 488 18. Hofmann A, Khorzom Y, Klimova A, Wolk S, Busch A, Sabarstinski P, Müglichs M,  
489 Egorov D, Kopaliani I, Poitz DM, Kapalla M, Hamann B, Frank F, Jänichen C, Brunssen  
490 C, Morawietz H, Reeps C. Associations of Tissue and Soluble LOX-1 with Human  
491 Abdominal Aortic Aneurysm. *J Am Heart Assoc.* 2023;12:e027537. doi:  
492 10.1161/JAHA.122.027537
- 493 19. Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale CP,  
494 Deanfield J, Smeeth L, Timmis A, Hemingway H. Type 2 diabetes and incidence of  
495 cardiovascular diseases: a cohort study in 1·9 million people. *Lancet Diabetes Endocrinol.*  
496 2015;3:105–113. doi: 10.1016/S2213-8587(14)70219-0
- 497 20. Tsai C-L, Lin C-L, Wu Y-Y, Shieh D-C, Sung F-C, Kao C-H. Advanced complicated  
498 diabetes mellitus is associated with a reduced risk of thoracic and abdominal aortic  
499 aneurysm rupture: a population-based cohort study. *Diabetes Metab Res Rev.*  
500 2015;31:190–197. doi: 10.1002/dmrr.2585
- 501 21. Julla J-B, Girard D, Diedisheim M, Saulnier P-J, Tran Vuong B, Blériot C, Carcarino E,  
502 Keizer J de, Orliaguet L, Nemazany I, Potier C, Khider K, Tonui DC, Ejlalmanesh T,  
503 Ballaire R, Mambu Mambuani H, Germain S, Gaborit B, Vidal-Trécan T, Riveline J-P,  
504 Garchon H-J, Fenaille F, Lemoine S, Carlier A, Castelli F, Potier L, Masson D, Roussel  
505 R, Vandiedonck C, Hadjadj S, Alzaid F, Gautier J-F, Venteclef N. Blood Monocyte  
506 Phenotype Is A Marker of Cardiovascular Risk in Type 2 Diabetes. *Circ Res.*  
507 2024;134:189–202. doi: 10.1161/CIRCRESAHA.123.322757
- 508 22. Hristov M, Weber C. Monocyte Subsets in Cardiovascular Disease: A Biomarker  
509 Perspective. *Thromb Haemost.* 2024. doi: 10.1055/a-2348-5697

- 510 23. Dregoesc MI, Țigu AB, Bekkering S, van der Heijden CDCC, Rodwell L, Bolboacă SD,  
511 Joosten LAB, Netea MG, Riksen NP, Iancu AC. Intermediate monocytes are associated  
512 with the first major adverse cardiovascular event in patients with stable coronary artery  
513 disease. *Int J Cardiol.* 2024;400:131780. doi: 10.1016/j.ijcard.2024.131780
- 514 24. Kitagawa A, Mastracci TM, Allmen R von, Powell JT. The role of diameter versus volume  
515 as the best prognostic measurement of abdominal aortic aneurysms. *J Vasc Surg.*  
516 2013;58:258–265. doi: 10.1016/j.jvs.2013.05.001
- 517 25. Vaitėnas G, Mosenko V, Račytė A, Medelis K, Skrebūnas A, Baltrūnas T. Abdominal  
518 Aortic Aneurysm Diameter versus Volume: A Systematic Review. *Biomedicines.*  
519 2023;11. doi: 10.3390/biomedicines11030941
- 520 26. Lindquist Liljeqvist M, Hultgren R, Gasser TC, Roy J. Volume growth of abdominal aortic  
521 aneurysms correlates with baseline volume and increasing finite element analysis-derived  
522 rupture risk. *J Vasc Surg.* 2016;63:1434-1442.e3. doi: 10.1016/j.jvs.2015.11.051
- 523 27. Berg KE, Ljungcrantz I, Andersson L, Bryngelsson C, Hedblad B, Fredrikson GN, Nilsson  
524 J, Björkbacka H. Elevated CD14++CD16- monocytes predict cardiovascular events. *Circ*  
525 *Cardiovasc Genet.* 2012;5:122–131. doi: 10.1161/CIRCGENETICS.111.960385
- 526 28. Hofmann A, Möglich M, Wolk S, Khorzom Y, Sabarstinski P, Kopaliani I, Egorov D,  
527 Horn F, Brunssen C, Giebe S, Hamann B, Deussen A, Morawietz H, Poitz DM, Reeps C.  
528 Induction of Heme Oxygenase-1 Is Linked to the Severity of Disease in Human  
529 Abdominal Aortic Aneurysm. *J Am Heart Assoc.* 2021;10:e022747. doi:  
530 10.1161/JAHA.121.022747
- 531 29. Koole D, Zandvoort HJA, Schoneveld A, Vink A, Vos JA, van den Hoogen LL, Vries J-  
532 PPM de, Pasterkamp G, Moll FL, van Herwaarden JA. Intraluminal abdominal aortic  
533 aneurysm thrombus is associated with disruption of wall integrity. *J Vasc Surg.*  
534 2013;57:77–83. doi: 10.1016/j.jvs.2012.07.003
- 535 30. Cameron SJ, Russell HM, Owens AP. Antithrombotic therapy in abdominal aortic  
536 aneurysm: beneficial or detrimental? *Blood.* 2018;132:2619–2628. doi: 10.1182/blood-  
537 2017-08-743237
- 538 31. Williams H, Mack C, Baraz R, Marimuthu R, Naralashetty S, Li S, Medbury H. Monocyte  
539 Differentiation and Heterogeneity: Inter-Subset and Interindividual Differences. *Int J Mol*  
540 *Sci.* 2023;24. doi: 10.3390/ijms24108757
- 541 32. Sagan A, Mrowiecki W, Mikolajczyk TP, Urbanski K, Siedlinski M, Nosalski R, Korbut  
542 R, Guzik TJ. Local inflammation is associated with aortic thrombus formation in  
543 abdominal aortic aneurysms. Relationship to clinical risk factors. *Thromb Haemost.*  
544 2012;108:812–823. doi: 10.1160/TH12-05-0339  
545